Cargando…

Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single-center, phase I, randomized, four-way crossover study

The aim of this study was to evaluate the effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers. Healthy volunteers were randomized to one of four treatment sequences (n = 112) involving four successive treatments in different order: pasireotide 600 µg (therapeutic dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Breitschaft, Astrid, Hu, Ke, Darstein, Christelle, Ligueros-Saylan, Monica, Jordaan, Pierre, Song, Dongweon, Hudson, Michelle, Shah, Rashmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4272414/ https://www.ncbi.nlm.nih.gov/pubmed/24242903 http://dx.doi.org/10.1002/jcph.213

Ejemplares similares

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial
por: Schopohl, Jochen, et al.
Publicado: (2014)

Effect of Tucatinib on Cardiac Repolarization in Healthy Volunteers
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2023)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Pasireotide for the Medical Management of Feline Hypersomatotropism
por: Scudder, C.J., et al.
Publicado: (2015)

Amino Acid Plasma Profiles from a Prolonged-Release Protein Substitute for Phenylketonuria: A Randomized, Single-Dose, Four-Way Crossover Trial in Healthy Volunteers
por: Scheinin, Mika, et al.
Publicado: (2020)

Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers
por: Huang, Jie, et al.
Publicado: (2018)

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Clinical use of pasireotide for Cushing’s disease in adults
por: Ceccato, Filippo, et al.
Publicado: (2015)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Effectiveness of low-dose pasireotide in a patient with Cushing’s disease: antiproliferative effect and predictivity of a short pasireotide suppression test
por: Grossrubatscher, Erika, et al.
Publicado: (2015)

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
por: del Corral, Adam, et al.
Publicado: (2012)

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
por: Golor, Georg, et al.
Publicado: (2012)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Pasireotide and octreotide in the treatment of severe late dumping syndrome
por: Mohammadi, Alireza, et al.
Publicado: (2017)

A prospective longitudinal study of Pasireotide in Nelson’s syndrome
por: Daniel, Eleni, et al.
Publicado: (2018)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
por: Zhao, Yuan, et al.
Publicado: (2021)

Pharmacokinetics and Bioequivalence of Fudosteine in Healthy Chinese Volunteers Under Fasting and Fed Conditions: A 4‐Way Replicate Crossover Study
por: Zhu, Mingxue, et al.
Publicado: (2022)

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies
por: Howard, Campbell, et al.
Publicado: (2014)

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
por: Manetti, Luca, et al.
Publicado: (2019)

Efficacy of pasireotide in controlling severe hypercortisolism until cardiac transplantation
por: Attanasio, Roberto, et al.
Publicado: (2017)

Rapid response of Nelson’s syndrome to pasireotide in radiotherapy-naive patient
por: He, Xin, et al.
Publicado: (2020)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Impact of pasireotide on postoperative pancreatic fistulas following distal resections
por: Vuorela, Tiina, et al.
Publicado: (2021)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Acute effects of Red Bull energy drink on ventricular repolarization in healthy young volunteers: a prospective study
por: Elitok, Ali, et al.
Publicado: (2016)

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study
por: Kallend, David, et al.
Publicado: (2022)

Diclofenac Prolongs Repolarization in Ventricular Muscle with Impaired Repolarization Reserve
por: Kristóf, Attila, et al.
Publicado: (2012)

Repolarization Heterogeneity: Beyond the QT Interval
por: Prenner, Stuart B., et al.
Publicado: (2016)

Is there an ideal way to initiate antiplatelet therapy with aspirin? A crossover study on healthy volunteers evaluating different dosing schemes with whole blood aggregometry
por: Meves, Saskia H, et al.
Publicado: (2011)

Pharmacokinetic Characterisation and Comparison of Bioavailability of Intranasal Fentanyl, Transmucosal, and Intravenous Administration through a Three-Way Crossover Study in 24 Healthy Volunteers
por: Nardi-Hiebl, S., et al.
Publicado: (2021)

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013)

Pasireotide therapy in a rare and unusual case of plurihormonal pituitary macroadenoma
por: Rajendran, Rajesh, et al.
Publicado: (2013)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Pasireotide Long‐Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism
por: Gostelow, R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k0b33okhrl4feb0ctfpttjn547